Changeflow GovPing Pharma & Drug Safety TREM2 antibodies patent, neurodegenerative dise...

Routine Notice Added

TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr

ChangeBridge: Patent Apps - Therapeutics (A61P)

Detected April 3rd, 2026

Summary

TREM2 antibodies patent, neurodegenerative disease treatment, 2nd Apr

View original document View source feed page

Source document (simplified)

← USPTO Patent Applications

TREM2 ANTIBODIES AND USES THEREOF

Application US20260092111A1 Kind: A1 Apr 02, 2026

Inventors

Michael FASSLER, Jacob GEORGE

Abstract

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). The anti-TREM2 antibodies or antigen-binding fragments thereof are useful, for example, in detecting TREM2 and in treating neurodegenerative diseases.

CPC Classifications

C07K 16/2803 A61P 25/28 A61P 29/00 A61K 2039/505 C07K 2317/24 C07K 2317/565 C07K 2317/76 C07K 2317/92

Filing Date

2025-06-10

Application No.

19234052

View original document →

Related changes

Markers for the Diagnosis of Biochemical Recurrence in Prostate Cancer

Routine Apr 03, 2026 • ChangeBridge: Patent Apps - Therapeutics (A61P) • Pharma & Drug Safety

CD28/OX40 Bispecific Antibodies for Solid Organ Transplant Rejection Treatment

Routine Apr 03, 2026 • ChangeBridge: Patent Apps - Therapeutics (A61P) • Pharma & Drug Safety

Anti-CTLA-4 Antibodies for Treating Adenoid Cystic Carcinoma

Routine Apr 03, 2026 • ChangeBridge: Patent Apps - Therapeutics (A61P) • Pharma & Drug Safety

Source

ChangeBridge: Patent Apps - Therapeutics (A61P) changeflow.com/changebridge/uspto-patent-applications/A61P

Pharma & Drug Safety

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency

USPTO

Instrument

Notice

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.